BIG
TEVA icon

Bellwether Investment Group’s Teva Pharmaceuticals TEVA Stock Holding History

Bellwether Investment Group’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-100
Closed -$3K – 552
2017
Q1 		$3K Sell
100
-1,609
-94% -$54.9K 0.01% 690
2016
Q4 		$62K Buy
+1,709
New +$68.2K 0.06% 244
2016
Q2 		$10K Buy
+205
New +$10.9K 0.01% 415

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bellwether Investment Group's TEVA Position: Q2 2017 in Review

Bellwether Investment Group sold out of Teva Pharmaceuticals (TEVA) in Q2 2017, closing a stake of 100 shares — an estimated $3K sold.

Bellwether Investment Group first reported a position in TEVA in Q2 2016 and held it in 3 quarters. The position peaked at $62K in Q4 2016. 648 funds tracked by Wall St. Rank hold TEVA as of Q2 2017.

  • Bellwether Investment Group reported no remaining Teva Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Bellwether Investment Group sold 100 Teva Pharmaceuticals shares in Q2 2017, an estimated $3K.
  • Bellwether Investment Group first reported a position in Teva Pharmaceuticals in Q2 2016 and held it in 3 quarters.
  • Bellwether Investment Group's Teva Pharmaceuticals position peaked at $62K in Q4 2016.
  • 648 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2017.

Based on Bellwether Investment Group's 13F filing for Q2 2017, filed 8 Aug 2017.